Related Experiment Videos
[Growth and endocrine function in major thalassemia]
F Pérignon1, R Brauner, J C Souberbielle
1l'Unité d'Endocrinologie Pédiatrique, Hôpital et Faculté Necker-Enfants Malades, Paris.
Archives Francaises De Pediatrie
|October 1, 1993
Summary
Patients with thalassemia major frequently experience endocrine issues like delayed puberty and hypoparathyroidism. Early intervention with hormone therapy can improve pubertal development and final height in these individuals.
Area of Science:
- Endocrinology
- Hematology
- Pediatrics
Context:
- Thalassemia major patients face high risks of secondary endocrine dysfunction.
- Improvements in hematologic care have not eliminated endocrine complications.
- This study investigates endocrine function in thalassemia major patients undergoing regular transfusions and iron chelation therapy.
Purpose:
- To evaluate the prevalence and types of endocrine dysfunction in patients with thalassemia major.
- To assess the impact of iron chelation therapy timing and dosage on endocrine outcomes.
- To monitor endocrine function over time and correlate with growth and pubertal development.
Summary:
- Growth hormone (GH) peak was normal, but somatomedin C levels were low. Peripheral hypothyroidism occurred in 6 patients.
- Low dehydroepiandrosterone sulfate was observed in 24 patients, potentially delaying pubic hair development. Diabetes mellitus was noted in 2 patients.
- Hypoparathyroidism affected 7 patients, and 12 experienced gonadotropin deficiency, leading to delayed puberty. Final mean height was -1.3 SD in both sexes.
Impact:
- Identifies delayed puberty due to gonadotropin deficiency, hypoparathyroidism, and hypothyroidism as the most frequent endocrine complications.
- Highlights the potential of substitution therapy with sex steroids to induce pubertal growth.
- Emphasizes the need for regular endocrine monitoring in thalassemia major patients to manage complications and optimize growth and development.